Senores Pharmaceuticals Limited held its ninth Annual General Meeting (AGM) on September 25, 2026. The meeting was conducted through video conferencing and other audio-visual means, complying with regulatory guidelines for virtual gatherings.

Shareholders approved several key resolutions during the session. The most significant corporate action was the approval of the Senores Pharmaceuticals Employee Stock Option Scheme 2026. This special resolution allows the company to grant stock options to employees, including those working in subsidiary companies, aiming to align employee interests with long-term shareholder value.

Director appointments and re-elections

The board composition saw minor changes with the re-appointment of existing directors and the induction of a new independent director. Mr. Sanjay Shaileshbhai Majmudar and Mr. Arpit Deepakkumar Shah were re-appointed as directors following their retirement by rotation. Additionally, Mr. Viranchi Arvindbhai Shah was appointed as a Non-Executive Independent Director for a term of five consecutive years.

Meeting proceedings and attendance

The AGM commenced at 11:31 am and concluded at 12:02 pm IST. A total of 49 members attended the meeting virtually, including representatives from corporate bodies. The meeting was chaired by Mr. Sanjay Shaileshbhai Majmudar, Chairman and Non-Executive, Non-Independent Director.

Key managerial personnel and auditors were present to address shareholder queries. M/s Pankaj R. Shah & Associates served as statutory auditors, while M/s Sharp and Tannan Associates acted as internal auditors. Mr. Mukesh H. Shah from M/s Mukesh H. Shah & Co. served as the secretarial auditor and scrutinizer for the voting process.

Resolutions passed

The following resolutions were transacted at the meeting:

Voting results required under Regulation 44(3) of the SEBI LODR Regulations will be submitted separately. The full proceedings are available on the company’s official website.

Senores Pharmaceuticals has successfully completed a USFDA inspection at its subsidiary Apnar Pharma, with one minor procedural observation raised and no issues identified related to Good Manufacturing Practices (GMP).

Inspection outcome at Apnar Pharma

The USFDA inspection at Apnar Pharma concluded with a single small procedural note. Importantly, inspectors found no deficiencies concerning GMP compliance, which governs the standards for manufacturing pharmaceutical products intended for the US market.

Key highlights of the inspection

• Facility inspected: Apnar Pharma (subsidiary of Senores Pharmaceuticals)
• Regulatory authority: USFDA
• Observation raised: One minor procedural note
• GMP status: No issues identified

A clean GMP outcome is significant for pharmaceutical manufacturers seeking to maintain or expand their product approvals and supply access in the United States. The single procedural observation, described as small, does not indicate any manufacturing quality concern based on the information disclosed.